Cybin Inc. Board of Directors

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Mr. Paul Glavine

Mr. Paul Glavine

Co-Founder, Chief Growth Officer & Director

Mr. Greg Cavers

Mr. Greg Cavers

Chief Financial Officer

Mr. Douglas L. Drysdale

Mr. Douglas L. Drysdale

Chief Executive Officer

Mr. Gabriel Fahel

Mr. Gabriel Fahel

Chief Legal Officer & Corporate Secretary

Mr. Aaron Bartlone

Mr. Aaron Bartlone

Chief Operating Officer

Ms. Lori Challenger

Ms. Lori Challenger

Chief Compliance, Ethics & Administrative Officer

Mr. George Tziras

Mr. George Tziras

Chief Business Officer & Director

Mr. Eric So L.L.B.

Mr. Eric So L.L.B.

Co-Founder, President & Executive Chairman

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.